中新网广州1月10日电 (记者 蔡敏婕)"肿瘤长期以来被视为人类健康的'头号杀手'，人类对抗肿瘤的理念 正发生根本性转变——从强调'你死我活'的抗癌模式，逐步迈向以'控瘤'为核心，最终实现'扶生及保 人'的整合医学新时代。"中国工程院院士、中国抗癌协会理事长樊代明10日通过视频在第二届广州国际 肿瘤热疗大会上表示，这一转变，为肿瘤治疗的发展指明了新方向。 热疗抗肿瘤主要是通过它的热效应，使肿瘤温度加热到40—43°C，并维持一定的时间。热疗可以杀死 肿瘤，主要是由于肿瘤血管壁发育不完全，内部的血管床结构很乱、血流很慢，热量容易停留，而正常 组织血管发育正常，可以通过血管扩张，加大血流量，把热量迅速散发出去，不会产生热滞留；因此热 疗时肿瘤局部温度往往高于周围组织5—10℃，直接或间接引起肿瘤细胞死亡，同时不损伤周围正常组 织。 樊代明指出，热疗技术历经持续迭代升级，其中中国在控温技术上的突破性进展，为腹腔肿瘤等诸多治 疗难题带来新的解决方案。 樊代明称，肿瘤物理治疗未来潜力巨大，但要推动热疗技术迈向极致，单靠医生群体远远不够，必须打 破学科壁垒，践行整合医学理念。 他提出，未来的肿瘤治疗研究，不仅需要医生之间 ...

中国科学院心理健康促进研究中心主任高文斌围绕"知、情、意、行"四个关键词讲解了建设心理能力的重要性，面对压力要如何积极应对，并主张 调节情绪也需要尊重自然规律。 活动现场，前外经贸部副部长龙永图，中国人民大学健康与医改政策实验室主任、医改研究中心主任王虎峰，中国工程院院士、中国抗癌协会理事 长樊代明，全国名中医、首届岐黄学者、北京中医药大学首席专家高思华，中国疾病预防控制中心慢病中心主任吴静，中国科学院心理健康促进研 究中心主任高文斌，中华慈善总会大健康工作委员会专家委员会副主任、中国民族医药学会心身医学分会会长纳贡毕力格等嘉宾举行圆桌对话并发 起倡议。 圆桌对话上，各位专家畅所欲言，围绕全民健康展开热烈讨论。前外经贸部副部长龙永图提出健康中国最重要的是让老百姓能够幸福和健康，他表 示"能够公平地享受医疗的资源，是我们中国和其他国家不一样的最重大区别之一"。 中国人民大学健康与医改政策实验室主任、医改研究中心主任王虎峰介绍了医改十年的研究评估情况，从发展指数看，国家层面健康中国建设发展 指数从2016年的50.38发展到2022年的86.27，整体呈现稳步上升态势，健康中国建设迈入新阶段。 中国工程院院士、中 ...

来源：环球网 12月23日，"健康中国行 赋能新生活"主题活动在北京成功举办。前外经贸部副部长龙永图，中国人民 大学健康与医改政策实验室主任、医改研究中心主任王虎峰，中国工程院院士、中国抗癌协会理事长樊 代明，全国名中医、首届岐黄学者、北京中医药大学首席专家高思华，中国疾病预防控制中心慢病中心 主任吴静，中国科学院心理健康促进研究中心主任高文斌，中华慈善总会大健康工作委员会专家委员会 副主任、中国民族医药学会心身医学分会会长纳贡毕力格等多位专家学者与行业代表共聚一堂，围 绕"加快建设健康中国"展开深度对话，凝聚行业智慧，共绘全民健康新蓝图。 （"健康中国行 赋能新生活"主题活动现场） 中华慈善总会大健康工作委员会专家委员会副主任、中国民族医药学会心身医学分会会长纳贡毕力格提 出，健康中国建设的核心是"全民健康"，医疗资源下沉对于促进社会公平与共同富裕具有重要作用，积 极推进大健康与慈善事业融合发展。 （圆桌对话现场） 主题活动上纳贡毕力格作为作为重要代表，与中国人民大学外国语学院、北京师范大学社会学院、上海 剑桥学院健康管理学院、北京大学外国语学院现场签署多项战略合作协议。此举标志着我国健康中国建 设在跨学科 ...

Core Insights - The "2025 China Health Industry Development and Rehabilitation Service Conference" will focus on technological innovation in the health sector, aligning with the "14th Five-Year Plan" to enhance self-reliance in health technology [2][5] - The health industry in China has seen significant growth, expanding from 7.4 trillion yuan to 12.3 trillion yuan over five years, with advancements in AI medical applications and CAR-T therapies [2][5] Academic Leadership - The conference will feature prominent academic figures, including academician Fan Daiming, who will discuss integrated medicine and its relevance to the "14th Five-Year Plan" [5][6] - Fan's presentation will focus on breakthroughs in the diagnosis and treatment of digestive diseases, emphasizing the importance of integrated prevention and management [5][6] Industry Practices - Over 50 leading companies from various sectors of the health industry will participate, covering innovative drug development, medical devices, healthcare services, health management, and digital health [8][9] - The conference will include roundtable discussions addressing key industry issues, such as investment opportunities in innovative drugs and the commercialization of brain-computer interfaces [9][10] Innovation and Collaboration - The event will facilitate direct interactions between experts and companies to address technological challenges and foster collaboration [6][12] - A showcase area will feature over 20 representative companies displaying their latest technologies and core products, enhancing visibility for industry innovations [12][13] Authoritative Results and Reports - The conference will release significant reports, including the "2025 China Health Industry White Paper" and the "Hua Xia ESG Dandelion 50-30 Index 2025 Annual Report," providing valuable insights and benchmarks for the industry [13][15] - The ESG report will evaluate 50 A-share companies and 30 H-share growth companies based on environmental, social, and governance criteria, supporting sustainable development in the health sector [13][15] Future Directions - The conference aims to create a continuous service platform for the health industry, ensuring that innovative practices and authoritative findings are effectively implemented [16][17] - The event will gather experts, industry leaders, and investment representatives to collaboratively shape the future of the health industry in China [16][17]

Core Insights - The conference highlighted a shift in diabetes treatment focus from merely controlling blood sugar to repairing pancreatic function, advocating for a new treatment direction supported by traditional Chinese medicine [1][2] - The "531 Diabetes Pancreatic Repair Project" aims to provide comprehensive support for over 230 million diabetes patients in China, addressing issues such as medication access and dietary management [1][2] Group 1: Current Diabetes Situation - As of now, there are approximately 233 million diabetes patients in China, with 90% suffering from type 2 diabetes and a noticeable trend of younger patients [1] - More than half of these patients struggle with poor blood sugar control, leading to complications like diabetic nephropathy and retinopathy, which are major causes of disability and death in the population [1] Group 2: Treatment Innovations - The conference emphasized the need for an integrated approach to diabetes treatment, viewing it as a systemic disease rather than focusing solely on blood sugar or insulin function [2] - The innovative exploration of traditional Chinese medicine, particularly the new drug "Wankang Island," exemplifies this advanced treatment philosophy [2] Group 3: Support Initiatives - The "531 Diabetes Pancreatic Repair Project" offers various support services, including precise learning resources, expert consultation channels, and dedicated lifestyle management for patients [2] - The initiative aims to resolve past challenges faced by patients, such as difficulties in medication adherence and dietary management [2]

Group 1 - The health and wellness industry is emerging as a new engine for the health economy post-pandemic, transitioning from the periphery to a central position [1] - The Fourth China (Macau) International High-Quality Consumption Expo and the Hengqin World Bay Area Forum were held from September 3 to 7, focusing on the integration of culture and tourism [1] - The forum featured a keynote speech by Lin Zhe'an, an academician from the Ukrainian National Academy of Sciences, emphasizing the need for integrated medical solutions and the use of AI and multidisciplinary decision-making [1] Group 2 - Lin Zhe'an proposed five scenarios to activate wellness consumption, including spa wellness, forest wellness, cellular wellness, traditional Chinese medicine wellness, and pet wellness [2] - The National Administration of Traditional Chinese Medicine has included "Traditional Chinese Medicine Wellness Bases" in the 14th Five-Year Plan, focusing on integrating AI and traditional medicine for personalized wellness solutions [2] - The integration of advanced technology with traditional medicine aims to create a digital platform for traditional Chinese medicine, providing comprehensive solutions from prevention to anti-aging [2]

Core Viewpoint - 盈康生命 reported a solid performance in the first half of the year, achieving revenue growth and net profit increase, indicating a trend of high-quality development in the company. Financial Performance - The company achieved operating revenue of 843 million yuan, a year-on-year increase of 2.4% [1] - Net profit attributable to shareholders reached 61.83 million yuan, up 12.8% year-on-year [1] - Deducting non-recurring gains and losses, the net profit was 60.59 million yuan, reflecting a year-on-year growth of 19.2% [1] - Gross margin improved by 0.5 percentage points, while expense ratio decreased by 2 percentage points, showcasing operational efficiency [1] Medical Services Development - The core business in medical services generated revenue of 653 million yuan, a year-on-year increase of 2.28% [2] - Revenue from oncology services reached 215 million yuan, growing by 25.14% year-on-year, with significant increases in patient visits and advanced surgical procedures [2] - The company has established a comprehensive service system covering early screening, diagnosis, mid-to-late stage treatment, and rehabilitation management [2] Strategic Expansion - The company expanded its regional presence by acquiring Changsha Kexin Tumor Hospital, enhancing its capabilities in minimally invasive tumor treatment [2] - The acquisition is expected to enrich the company's oncology pre-diagnosis and treatment ecosystem, providing additional growth momentum [2] Innovative Service Offerings - The company is focused on integrating medicine with new technologies and experiences to meet diverse health needs [3] - New services include weight loss, precision anti-aging, and international medical services, alongside the introduction of over 100 new clinical technologies [3] - The company has pioneered brain-machine interface applications in healthcare, achieving notable surgical outcomes in Parkinson's treatment [3] AI Integration and Efficiency - The company has implemented a "medical + AI" strategy, leading to significant improvements in service capacity and operational efficiency [4] - Key metrics include a 10% increase in per capita service volume and a 2 percentage point reduction in overall expense ratio [4] - AI technologies have reduced surgical complications by 10% and improved various operational efficiencies, including a 66% increase in imaging diagnosis efficiency [4] Market Growth in Medical Devices - The company achieved a 35% year-on-year growth in overseas medical device revenue, driven by strategic market expansion [5] - In the domestic market, the company has upgraded its products and channels, achieving over 40% coverage in top-tier hospitals [5] - The company’s infusion pumps and mammography equipment have gained significant market share, ranking third in their respective categories [5] Global Market Strategy - The company employs a "one country, one policy" strategy for overseas market expansion, enhancing user experience and product application [6] - New partnerships with nine overseas distributors have been established, expanding coverage across multiple global regions [6]

Group 1 - The core theme of the 2025 West China Conference is "Integration and Coexistence for a Healthy Future," addressing the complexities of disease and diverse health needs through integrative medicine [1][2] - The conference emphasizes breaking down disciplinary barriers and integrating technologies like AI to transform the healthcare system towards "whole life cycle health management" [2][8] - The event gathers top hospital managers, clinical experts, and researchers from various provinces to explore the integration of clinical, research, and industrial forces in healthcare [1][2] Group 2 - The main forum highlights the importance of medical data asset construction and its foundational role in healthcare innovation [2][8] - Experts discuss the integration of rehabilitation technologies for cancer management and the shift from treating diseases to treating individuals, focusing on personalized care [2][8] - The forum aims to enhance resource optimization and improve health governance efficiency through collaborative practices [2][8] Group 3 - The integration of medical, insurance, and pharmaceutical sectors is discussed to promote standardized clinical practices and improve healthcare management [8][10] - The forum presents significant findings on endocrine therapy in early breast cancer treatment, advocating for the use of specific medications based on clinical evidence [8][10] - Experts reach a consensus on the need for better communication among medical, insurance, and pharmaceutical sectors to balance regulatory policies and clinical practices [11] Group 4 - The Orthopedic Forum showcases advancements in orthopedic treatment and the integration of traditional and modern medicine [12][18] - Experts present innovative approaches in bone regeneration and repair, emphasizing the importance of interdisciplinary collaboration [12][18] - The forum serves as a platform for sharing clinical experiences and strategies in addressing complex orthopedic challenges [12][18] Group 5 - The West China Conference is positioned as a pivotal hub for connecting clinical needs with research and innovation, marking a significant evolution in the healthcare ecosystem [19][20] - The conference aims to support the development of a comprehensive ecosystem that integrates policy, technology, capital, and market dynamics [19][20] - Future agendas include discussions on digital marketing challenges, building payment closures in healthcare, and exploring global innovation opportunities [20]

Core Insights - The event marked the recognition of China Resources Pharmaceutical Group as a member of the China Anti-Cancer Association, highlighting the collaboration between the two entities in cancer prevention and treatment [2][4][6] Group 1: Event Overview - The event was themed "Empowerment through Integration" and included a visit to the innovation center of China Resources Pharmaceutical Group, showcasing its patient-centered innovations over 75 years [4][5] - Key figures from the China Anti-Cancer Association, including its president and vice presidents, attended the event, emphasizing the importance of collaboration in cancer treatment [2][6] Group 2: Strategic Initiatives - The China Anti-Cancer Association introduced 17 strategic measures under the guidance of integrated medicine, aiming to enhance cancer prevention and treatment in China [5][6] - The association's "China Cancer Integrated Diagnosis and Treatment Guidelines" established a comprehensive system for cancer care, including over 70 technical guidelines and 60 cancer type guidelines [5][6] Group 3: Industry Collaboration - China Resources Pharmaceutical Group aims to integrate resources across research, education, and application to improve patient access to innovative drugs, positioning itself as a leader in the pharmaceutical distribution sector [6][9] - The company plans to enhance collaboration with the China Anti-Cancer Association to build a new ecosystem for cancer prevention and treatment, supporting the Healthy China strategy [6][9] Group 4: Challenges and Opportunities - The Chinese pharmaceutical industry is entering a new phase driven by product innovation, but faces challenges such as shortened product life cycles and commercialization difficulties [6][9] - The company is leveraging its extensive distribution network and experience to improve patient accessibility and address the challenges in drug availability and payment [6][9]